AZYO Aziyo Biologics

Aziyo Biologics to Participate in Upcoming Investor Conferences

Aziyo Biologics to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced that management will be participating in the following investor conferences:

34th Annual Piper Sandler Healthcare Conference

Location: New York, NY

Format: Fireside chat and 1x1 meetings

Date: December 1, 2022

Time: 11:30 a.m. ET

Participants: C. Randall Mills, Ph.D., President and Chief Executive Officer, and Matthew Ferguson, Chief Financial Officer

Cantor Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference

Location: Miami, FL

Format: Panel discussion entitled “R&R: Regenerative & Restoration Medicine” and 1x1 meetings

Date: December 8, 2022

Time: 2:45 p.m. ET

Participant: C. Randal Mills, Ph.D.

A webcast of the fireside chat at the Piper Sandler conference can be accessed by visiting . A replay will be available on the Company's website following the event. A recording of the panel discussion at the Cantor conference will be made available only to clients of Cantor Fitzgerald.

About Aziyo Biologics

Aziyo Biologics is a regenerative medicine company with a commercial portfolio of differentiated products focused on improving outcomes in patients undergoing a range of surgical procedures, primarily for implantable medical devices. Since its founding in 2015, the Company has created a portfolio of commercial-stage products used in cardiovascular, orthopedic, and reconstructive specialties. For more information, visit .

Investors:

Matt Ferguson

Aziyo Biologics, Inc.

Media:

Courtney Guyer

Aziyo Biologics, Inc.



EN
21/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adopti...

Elutia Delivers Robust Growth on the Strength of EluPro™ Market Adoption EluPro™ Q2 revenue up 49% sequentially; Elutia advances next-generation drug-eluting biomatrix for breast reconstruction Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the second quarter of 2025. Since full launch in January 2025, EluPro has rapidly established itself as the preferred antibi...

 PRESS RELEASE

Elutia to Report Second Quarter 2025 Financial Results on Thursday, Au...

Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its second quarter 2025 financial results after market close on Thursday, August 14, 2025. Members of the Company’s management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following informati...

 PRESS RELEASE

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medic...

Dr. Michelle LeRoux Williams Earns Washington Business Journal’s Medical Device Innovator Award GAITHERSBURG, Md., July 31, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Michelle LeRoux Williams, Chief Scientific Officer, has been awarded the Medical Device Innovator Award by the Washington Business Journal. This award recognizes Dr. Williams’ groundbreaking contributions to the medical device industry, particularly her leadership in the development and successful commercializatio...

 PRESS RELEASE

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platfor...

New Evidence Supports the Value of Elutia’s Antibiotic-Eluting Platform for Implantable Devices — The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the . Researchers ...

 PRESS RELEASE

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Me...

Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope’s impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product Launches—in the 2025 Medical Device Network Excellence Awards. The awards celebrate El...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch